Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

Benzinga · 1d ago
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.